Duyuru • 1h
Betterlife Pharma Engages Nucro-Technics to Complete the Last Glp Toxicology Study of Betr-001 Required by the Fda for Ind and Phase 1 BetterLife Pharma Inc. has entered into an agreement with Nucro-Technics Inc. to conduct the last IND-enabling GLP toxicology study with BETR-001 for its planned IND and Phase 1 program. BETR-001 is 2-bromo-lysergic acid diethylamide (2-Br-LSD), a non-hallucinogenic derivative of LSD. BETR-001 is a potent neuroplastogen and an agonist of the 5-HT1B, 5-HT1D, and 5-HT1F receptors, which are clinically validated targets of migraine therapies, as well as the 5-HT2A receptors. BETR-001 is being developed initially for migraine and cluster headache, two disabling headache disorders with substantial unmet medical needs. The BETR-001 IND filing is projected for the First Quarter 2027. Duyuru • Jun 23
BetterLife Pharma Inc. announced that it has received CAD 2 million in funding On June 22, 2026, BetterLife Pharma Inc. has closed the transaction. Duyuru • Jun 16
BetterLife Pharma Inc. announced that it expects to receive CAD 2 million in funding BetterLife Pharma Inc. has announced a non-brokered private placement of 10% convertible debenture of the company to raise gross proceeds of CAD 2,000,000 on June 15, 2026. The debenture are 100% convertible into common units of the company at a conversion price value of CAD 0.06 per unit and carry interest rate of 10% and with each unit comprising of one common share and one share purchase warrant exercisable at CAD 0.10 for three years from issuance. All securities issued in connection with the Financing will be subject to a statutory hold period of four months and one day from the date of issuance in accordance with applicable Canadian securities laws. A director and insider of the company intends to participate in the financing by subscribing for CAD 2,000,000 of the Debenture. The bonds will mature one year from closing. The transaction is expected to close on June 25, 2026. Duyuru • Apr 18
BetterLife Pharma Inc. announced that it has received CAD 0.4996 million in funding On April 17, 2026, BetterLife Pharma Inc. closed the transaction. Dr. Ahmad Doroudian, chief executive officer of the company, subscribed for a total of 1,250,000 units under the offering. Duyuru • Apr 09
BetterLife Pharma Inc. announced that it expects to receive CAD 0.5 million in funding BetterLife Pharma Inc announced non-brokered private placement offering to issue 7,142,857 unit at an issue price of CAD 0.07 for the proceeds of CAD 499,999.99 on April 8, 2026. Each unit consisting of one common share in the capital of the company and one full common share purchase warrant. Each warrant will entitle the holder to purchase one common share at an exercise price of CAD 0.10 for up to two years following the date of the closing of the private placement. The offering is expected to close on or about April 17, 2026, and is subject to execution of agreements by the placees and to certain conditions, including, but not limited to, the receipt of all necessary regulatory approvals, including the approval of the Canadian Securities Exchange. All securities issued in connection with the offering will be subject to a four-month-and-one-day statutory resale restriction pursuant to applicable Canadian securities laws. Duyuru • May 28
Betterlife Pharma Inc. Provides Scientific Update on Neuroplastogenic Activity of Betr-001 BetterLife Pharma Inc. recently presented a scientific update at Bloom Burton Conference on May 5, 2025 in Toronto, Canada. The emerging new paradigm in treating psychiatric and neurological disorders is the ability of a drug to enable the brain to rewire by growing new dendrites and spines, which enables new connections between neurons. Thisphenon is called neuroplasticity and the drug that is able to induce such an effect is called a neuroplastogen. BetterLife reported data at the Bloom Burton Conference showing that BETR-001 is a potent neuroplastogen. Only BETR-001 treatment was able to significantly induce formation of new spines (green stain) in cultured neurons. Based on its excellent neuroplasticity data, its neuroreceptor activation profile and preliminary data obtained in animal models, BETR-001 is projected to be effective in treating various psychiatric and neurological disorders including depression, anxiety, PTSD, traumatic brain injury, migraines and neuropathic pain. BETR-001 is non-hallucinogenic and not a controlled substance. BetterLife has been granted a composition of matter patent on BETR-001 by the USPTO. BetterLife has had its BETR-001 pre-IND meeting with the FDA and has completed most of the required IND-enabling studies. The BETR-001 IND filing and start of human trials are projected for first first half of 2026. Duyuru • May 19
BetterLife Pharma Inc., Annual General Meeting, Jul 23, 2025 BetterLife Pharma Inc., Annual General Meeting, Jul 23, 2025. Duyuru • May 15
BetterLife Pharma Inc. Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric Disorders BetterLife Pharma Inc. recently presented a scientific update at Bloom Burton Conference on May 5, 2025 in Toronto, Canada. BetterLife reported that its proprietary compound, BETR-001, is showing very promising preclinical data of its breakthrough ability to provide therapeutic effect in depression/an anxiety animal models. Current methods of treating depression/an anxiety primarily focus on increasing the level of one of the three neurotransmitters: serotonin, norepinephrine and/or dopamine in the brain. Each neurotransmitter has different receptor targets, and each receptor performs different functions. Current treatments are usually reuptake inhibitors such as SSRIs (selective serotonin reuptake inhibitors) and by increasing the amount of a neurotransmitter, all its receptors are activated. What is needed are new treatments that activate the neuroreceptors themselves, and more importantly, only selective subsets of these receptors. The therapeutic effects of BETR-001 seen in preclinical models are primarily driven by its activation (agonism) of serotonin's 5HT2A receptor. Not only does BETR-001 activate the 5HT2A receptor, which plays a key role in depression/an anxiety, this activation is via a mechanism that allows for a highly efficacious therapeutic effect without hallucinogenic side effects. This stands in contrast to other potent 5HT2A activators, such as LSD, psilocybin and other psychedelics. BetterLife has reported on the details of BETR-001 activation of the 5HT2A receptor previously (Lewis et al., Cell Reports, 2023). Recently studies have shown that the activation of the 5 HT2A receptor above 70% leads to hallucination (Wallach et al., Nature Communications, 2023). BetterLife believes that BETR-001's novel mechanism of action provides a new paradigm for treatment of psychiatric disorders such as depression, anxiety and PTSD. It activates the 5HT2A receptor partially but stays below the hallucination threshold. In addition, unlike LSD, psilocybin, MDMA and other such agents BETR-001 is not an activator of the 5HT2B receptor. Activation of 5HT2B has been linked to cardiac safety. The neuroreceptor selectivity of BETR-001 in this regard is another of its key advantages over other competitor agents. An additional benefit of BETR-001 is that repeated dosing does not induce tolerance, unlike classic agents like LSD. This allows daily administration if needed. Furthermore, the lack of hallucinations with BETR-001 means it is a non-controlled substance and patient self-administration at home is possible. Finally, an overarching property of BETR-001 is a very potent neuroplastogen. BetterLife has been granted a composition of matter patent on BETR-001 by the USPTO. BetterLife has had its BETR-001 pre-IND meeting with the FDA and has completed most of the required IND-enabling studies. The BETR-001 IND filing and start of human trials are projected for H1 2026. BetterLife is considering the development of BETR-001 for treatment of various psychiatric and neurological disorders. BETR-001 for treatment the treatment of various psychiatric and neurological diseases. Duyuru • Mar 31
BetterLife Pharma Inc. Appoints Steven Sangha to its Board of Directors BetterLife Pharma Inc. announced it has appointed Dr. Steven Sangha to its Board of Directors. Dr. Sangha has over 25 years of business experience, including investment banking, business development and asset management. His extensive background with public company governance, compliance and finance has led him to run a successful Private Fund Family Office. Dr. Sangha holds a Doctorate of Dental Surgery from the University of Western Ontario in London, Ontario, and a Bachelor of Pharmaceutical Science from the University of British Columbia in Vancouver, British Columbia. Duyuru • Nov 27
BetterLife Pharma Inc. Obtains Cardiac Safety Data for BETR-001 BetterLife Pharma Inc. announced it has completed one of its IND-enabling cardiac safety studies of BETR-001. These GLP in vitro studies demonstrated that BETR-001 has minimal impact on the human ether- a-go-go-related gene (hERG) channel, an important ion channel for cardiac functioning. Duyuru • Oct 23
BetterLife Pharma Inc. Obtains Favourable Genotoxicity Data for Oral BETR-001 BetterLife Pharma Inc. announced it has completed one of its IND-enabling genotoxicity studies of BETR-001. The studies demonstrated that oral BETR-001, even at very high doses, does not show any evidence of bone marrow toxicity or mutagenic (DNA mutation) and clastogenic (chromosome damage) activities. The GLP genotoxicity studies conducted on BETR-001 included in vitro bacterial reverse mutation assay, in vitro micronucleus test, and in vivo micronucleus test in male and female rats. These studies are a critical component of the safety assessment required by the U.S. Food and Drug Administration (FDA) and needed for entry into clinical trials. Duyuru • Aug 29
BetterLife Pharma Inc. announced that it expects to receive CAD 1.1 million in funding BetterLife Pharma Inc announced a non brokered private placement offering of 7,333,333 units issued at a price of CAD 0.15 per unit for gross proceeds CAD 1,099,999.95 on August 29, 2024. Each unit consisting of one common share in the capital of the Company and one full common share purchase warrant. Each Warrant will entitle the holder to purchase one Common Share at an exercise price of CAD 0.20 for up to two years following the date of the closing of the Private Placement. The close is subject to the receipt of all necessary regulatory and other approvals which will be announced as soon as it has been completed. Duyuru • Jul 03
BetterLife Pharma Inc. announced that it has received CAD 0.175 million in funding On July 2, 2024, BetterLife Pharma Inc. closed the transaction. Duyuru • May 15
BetterLife Obtains Excellent Animal Cardiopulmonary Safety Data for Oral BETR-001 BetterLife Pharma Inc. announced it has completed its animal GLP cardiopulmonary safety study of BETR-001. The study demonstrated that oral BETR-001 at doses over 100-fold the projected starting dose in upcoming human trials did not show any significant cardiopulmonary pharmacological safety issues in animals. Cardiopulmonary safety (also known as telemetry) studies investigate the effect of a drug in animals using surgically implanted transmitters to assess blood pressure, electrocardiography (ECG), lung respiration, body temperature, and general activity level. The BETR-001 cardiopulmonary study found no BETR-001 related effects on ECG intervals, respiratory parameters, core body temperature, or activity levels. Duyuru • May 03
BetterLife Pharma Inc. Advances BETR-001 IND-Enabling Studies BetterLife Pharma Inc. announced that it has advanced in its IND-enabling studies for BETR-001, a non-hallucinogenic derivative of LSD (lysergic acid diethylamide). The IND-enabling metabolism and genotoxicity GLP studies have been initiated. BetterLife has had its BETR-001 pre-IND meeting with the FDA, and projects to file the BETR-001 IND by end of 2024. Duyuru • Apr 13
BetterLife Pharma Inc., Annual General Meeting, Jun 25, 2024 BetterLife Pharma Inc., Annual General Meeting, Jun 25, 2024. Duyuru • Mar 05
BetterLife Pharma Inc. announced that it expects to receive CAD 0.1 million in funding BetterLife Pharma Inc. announced a private placement to issue convertible debentures for the gross proceeds of CAD 100,000 on March 4, 2024. The transaction will include participation from individual investor such as Ahmad Doroudian for CAD 100,000. Duyuru • Mar 04
BetterLife Pharma Inc. announced that it has received CAD 0.065 million in funding BetterLife Pharma Inc. announced a private placement to issue 10% convertible debentures for the gross proceeds of CAD 65,000 on March 4, 2024. The Convertible Debentures are convertible at the option of the holder into units of the Company, consisting of one common share and one share purchase warrant, at a conversion price of CAD 0.10 per unit. Each share purchase warrant will have an exercise price of CAD 0.10 and will expire on August 31, 2026. The debentures bear 10% interest rate and matures on February 28, 2026. Duyuru • Jan 02
BetterLife Pharma Inc. announced that it has received CAD 0.3 million in funding BetterLife Pharma Inc. announce that it has closed a non-brokered private placement of 10% convertible debentures for principal[al amount of CAD 300,000 on January 2, 2024. The convertible debenture interest rate of 10%, will mature on June 30, 2025. The Convertible Debentures are convertible at the option of the holder into units of the Company, consisting of one common share and one share purchase warrant, at a conversion price of CAD 0.10 per unit. Each share purchase warrant will have an exercise price of CAD 0.10 and will expire on December 31, 2025. The transaction included participation from Dr. Ahmad Doroudian, Chief Executive Officer of the Company who subscribed a total of CAD 125,000 principal amount of convertible debentures under the Offering. Duyuru • Dec 18
BetterLife Pharma Inc. announced that it has received CAD 0.2 million in funding BetterLife Pharma Inc. announce that it has closed a non-brokered private placement of 2,000,000 units at an issue price of CAD 0.10 per Unit for aggregate gross proceeds of CAD 200,000 on December 18, 2023. Each Unit is comprised of one common share and one warrant. Each warrant entitles the holder thereof to acquire one common share at an exercise price of CAD 0.10 at any time up to 24 months from the closing of the Offering. The Units sold pursuant to the Offering will be subject to a four month hold period pursuant to applicable Canadian securities laws. The transaction included participation from Dr. Ahmad Doroudian, Chief Executive Officer of the Company who subscribed a total of 1,000,000 Units under the Offering. Duyuru • Dec 01
Us Patent and Trademark Office Publishes Betterlife’S Comprehensive Patent for Betr-001 and Other Lsd Derivatives BetterLife Pharma Inc. announced that its patent application for BETR-001 and LSD derivatives titled “LSD derivatives, synthesis & method for treatment of diseases and disorders” has been published by the United States Patent and Trademark Office under publication number US-2023/0357243-A1 and available for access on USPTO’s databases. BetterLife is presently developing one of these derivatives: a 2-bromo derivative of LSD (BETR-001) that is non-hallucinogenic and, in preclinical animal models, has been shown to be a potent neuroplastogen and have efficacy against depression/anxiety states. This published U.S. patent is part of a developing international patent portfolio which cover new compositions of 2-bromo-LSD and other LSD derivatives. In addition to composition claims, these applications also cover a novel method for making non-hallucinogenic LSD derivatives that does not involve the use of controlled substances at any stage. The applications also cover use of these derivatives in the treatment of a range of neuropsychiatric and neurological conditions, including depression, anxiety, cluster headaches and neuropathic pain. Betterlife is also pleased that its efforts to develop novel therapies for mental disorders were highlighted in the November 8 edition of The Atlantic. The Atlantic journal highlighted the potential of the BETR-001 program, as a non-hallucinogenic analog of LSD, in an article entitled “What If Psychedelics’ Hallucinations Are Just a Side Effect?” The article discusses, in part, that a growing number of key opinion leaders in neuroscience now believe that the hallucination caused by psychedelics is just a side effect and not necessary to produce mental-health benefits by this class of drugs. BETR-001 is currently undergoing IND-enabling studies and projected to enter human trials in 2024. Duyuru • Jul 14
BetterLife Pharma Inc. announced that it has received CAD 0.22 million in funding BetterLife Pharma Inc. announced a non-brokered private placement of 2,200,000 units at a price of CAD 0.10 per non-brokered unit for aggregate gross proceeds of CAD 220,000 on July 13, 2023. Each non-brokered unit is comprised of one common share and one warrant. Each warrant entitles the holder thereof to acquire one common share at an exercise price of CAD 0.15 at any time up of 60 months from the closing of the offering. The units sold pursuant to the offering will be subject to a four month hold period pursuant to applicable Canadian securities laws. Duyuru • Jun 23
BetterLife Pharma Inc. Announces Appointment of Steven Sangha as Corporate Development Advisor BetterLife Pharma Inc. announced the appointment of Dr. Steven Sangha as corporate development advisor to the Company. Dr. Sangha has over 25 years of experience in investment banking, business development and asset management. His extensive experience with public company governance and compliance, and finance has led him to successfully run a Private Fund Family Office. Dr. Sangha’s interest in the biotechnology industry has allowed positive growth for early-stage companies with his consummate efforts in assessment, development and financial support. Dr. Sangha holds a Doctorate of Dental Surgery from the University of Western Ontario in London, Ontario, and a Bachelor of Pharmaceutical Science from the University of British Columbia in Vancouver, British Columbia. Duyuru • Jun 09
BetterLife Pharma Inc. Continues Progress on BETR-001 IND-Enabling Studies BetterLife Pharma Inc. announced that the IND-enabling studies BetterLife's 2-bromo-LSD ("BETR -001") continue to progress. BETR-001 is a non-hallucinogenic Lysergic Acid Diethylamide ("LSD") derivative molecule. BetterLife has previously completed the preclinical pharmacological profiling of BETR-001, which showed that BETR-001 has robust activity in various depression/an anxiety animal models without hallucinogenic activity. The BETR-001 IND-enabling animal toxicology studies are now in various stages of completion. The in-life portion of the 28-day repeat dose GLP toxicology study in dogs has now been completed, and the histopathological analyses are ongoing. The GMP manufacturing of BETR-001 drug substance is also in its final stages. 
